Login to Your Account

Adamas launches pivotal trial of CNS drug

By Michael Fitzhugh
Staff Writer

Tuesday, June 10, 2014
Adamas Pharmaceuticals Inc., primed by a recent $25 million milestone payment on an unrelated program, is starting a pivotal phase III study to test the ability of ADS-5102, its experimental extended-release formulation of generic drug amantadine, to quell involuntary movements tied to Parkinson's disease (PD) treatment.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription